Literature DB >> 27514751

Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.

Jenica N Upshaw1, Marvin A Konstam2, David van Klaveren2, Farzad Noubary2, Gordon S Huggins2, David M Kent2.   

Abstract

BACKGROUND: Outpatients with heart failure (HF) who are at high risk for HF hospitalization and death may benefit from early identification. We sought to develop and externally validate a model to predict both HF hospitalization and mortality that accounts for the semicompeting nature of the 2 outcomes and captures the risk associated with the transition from the stable outpatient state to the post-HF hospitalization state. METHODS AND
RESULTS: A multistate model to predict HF hospitalization and all-cause mortality was derived using data (n=3834) from the HEAAL study (Heart Failure Endpoint evaluation of Angiotensin II Antagonist Losartan), a multinational randomized trial in symptomatic patients with reduced left ventricular ejection fraction. Twelve easily and reliably obtainable demographic and clinical predictors were prespecified for model inclusion. Model performance was assessed in the SCD-HeFT cohort (Sudden Cardiac Death in Heart Failure Trial; n=2521). At 1 year, the probability of being alive without HF hospitalization was 94% for a typical patient in the lowest risk quintile and 77% for a typical patient in the highest risk quintile and this variability in risk continued through 7 years of follow-up. The model c-index was 0.72 in the derivation cohort, 0.66 in the validation cohort, and 0.69 in the implantable cardiac defibrillator arm of the validation cohort. There was excellent calibration across quintiles of predicted risk.
CONCLUSIONS: Our findings illustrate the advantages of a multistate modeling approach, providing estimates of HF hospitalization and death in the same model, comparison of predictors for the different outcomes and demonstrating the different trajectories of patients based on baseline characteristics and intermediary events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00000609 and NCT00090259.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  death; heart failure; hospitalization

Mesh:

Substances:

Year:  2016        PMID: 27514751      PMCID: PMC5328587          DOI: 10.1161/CIRCHEARTFAILURE.116.003146

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  35 in total

1.  Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community.

Authors:  Kumar Narayanan; Kyndaron Reinier; Audrey Uy-Evanado; Carmen Teodorescu; Harpriya Chugh; Eloi Marijon; Karen Gunson; Jonathan Jui; Sumeet S Chugh
Journal:  Circulation       Date:  2013-09-18       Impact factor: 29.690

2.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.

Authors:  K D Aaronson; J S Schwartz; T M Chen; K L Wong; J E Goin; D M Mancini
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

Review 4.  Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review.

Authors:  Ana C Alba; Thomas Agoritsas; Milosz Jankowski; Delphine Courvoisier; Stephen D Walter; Gordon H Guyatt; Heather J Ross
Journal:  Circ Heart Fail       Date:  2013-07-25       Impact factor: 8.790

5.  Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).

Authors:  Michel Komajda; Peter E Carson; Scott Hetzel; Robert McKelvie; John McMurray; Agata Ptaszynska; Michael R Zile; David Demets; Barry M Massie
Journal:  Circ Heart Fail       Date:  2010-11-10       Impact factor: 8.790

6.  Eligibility and utilization of implantable cardioverter-defibrillators in a regional STEMI system.

Authors:  Benjamin K Johnson; Ross F Garberich; Timothy D Henry; William T Katsiyiannis; Jay Sengupta; Ankur Kalra; Robert G Hauser; Meghan E Lardy; Marc C Newell
Journal:  Heart Rhythm       Date:  2015-10-13       Impact factor: 6.343

7.  The Seattle Heart Failure Model: prediction of survival in heart failure.

Authors:  Wayne C Levy; Dariush Mozaffarian; David T Linker; Santosh C Sutradhar; Stefan D Anker; Anne B Cropp; Inder Anand; Aldo Maggioni; Paul Burton; Mark D Sullivan; Bertram Pitt; Philip A Poole-Wilson; Douglas L Mann; Milton Packer
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

8.  Development and validation of a clinical index to predict survival after cardiac resynchronisation therapy.

Authors:  F Leyva; P W X Foley; B Stegemann; J A Ward; L L Ng; M P Frenneaux; F Regoli; R E A Smith; A Auricchio
Journal:  Heart       Date:  2009-07-09       Impact factor: 5.994

9.  Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.

Authors:  Marvin A Konstam; Philip A Poole-Wilson; Kenneth Dickstein; Helmut Drexler; Steven J Justice; Michel Komajda; William Malbecq; Felipe A Martinez; James D Neaton; Gunter A J Riegger; Soneil Guptha
Journal:  Eur J Heart Fail       Date:  2008-09-02       Impact factor: 15.534

10.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Authors:  Marvin A Konstam; James D Neaton; Kenneth Dickstein; Helmut Drexler; Michel Komajda; Felipe A Martinez; Gunter A J Riegger; William Malbecq; Ronald D Smith; Soneil Guptha; Philip A Poole-Wilson
Journal:  Lancet       Date:  2009-11-16       Impact factor: 79.321

View more
  7 in total

1.  Short-Term Mortality in Patients with Heart Failure at the End-of-Life Stages: Hades Study.

Authors:  Miguel Angel Muñoz; Esther Calero; Julio Duran; Elena Navas; Susana Alonso; Nuria Argemí; Marta Casademunt; Patricia Furió; Elena Casajuana; Nuria Torralba; Nuria Farre; Rosa Abellana; José-Maria Verdú-Rotellar
Journal:  J Clin Med       Date:  2022-04-19       Impact factor: 4.964

2.  Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model.

Authors:  Jenica N Upshaw; David van Klaveren; Marvin A Konstam; David M Kent
Journal:  Am J Med       Date:  2017-12-25       Impact factor: 4.965

3.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

4.  Retrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experience.

Authors:  Michael M Hammond; Changyu Shen; Stephanie Li; Dhruv S Kazi; Marwa A Sabe; A Reshad Garan; Lawrence J Markson; Warren J Manning; Allan L Klein; Sherif F Nagueh; Jordan B Strom
Journal:  PLoS One       Date:  2020-12-22       Impact factor: 3.240

5.  A multistate model of health transitions in older people: a secondary analysis of ASPREE clinical trial data.

Authors:  Johannes T Neumann; Le T P Thao; Emily Callander; Prudence R Carr; Vazhma Qaderi; Mark R Nelson; Christopher M Reid; Robyn L Woods; Suzanne G Orchard; Rory Wolfe; Galina Polekhina; Jeff D Williamson; James M Trauer; Anne B Newman; Anne M Murray; Michael E Ernst; Andrew M Tonkin; John J McNeil
Journal:  Lancet Healthy Longev       Date:  2022-02-07

6.  Evaluating risk prediction models for adults with heart failure: A systematic literature review.

Authors:  Gian Luca Di Tanna; Heidi Wirtz; Karen L Burrows; Gary Globe
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

Review 7.  Predictive approaches to heterogeneous treatment effects: a scoping review.

Authors:  Alexandros Rekkas; Jessica K Paulus; Gowri Raman; John B Wong; Ewout W Steyerberg; Peter R Rijnbeek; David M Kent; David van Klaveren
Journal:  BMC Med Res Methodol       Date:  2020-10-23       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.